Web Analytics
Cổ phiếu HROW (NASDAQ) | HARROW HEALTH INC – Phân tích Deepscope
MARKET

Select Market Data Region

HROW — HARROW HEALTH INC (Healthcare >> Drug Manufacturers - Specialty & Generic)

HROW FAQ

What is HROW's P/E ratio?

HARROW HEALTH INC (HROW) currently trades at a P/E ratio of 96.90.

What is HROW's ROE?

HARROW HEALTH INC reports a Return on Equity (ROE) of -52.12%.

What is HROW's dividend yield?

HARROW HEALTH INC offers a dividend yield of 0.00%.

What is HROW's Deepscope Quality Score?

Deepscope rates HROW's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy HROW?

Deepscope's AI Timing Score for HROW is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does HROW belong to?

HARROW HEALTH INC is classified under the Healthcare >> Drug Manufacturers - Specialty & Generic sector on the NASDAQ exchange.

Stock Check   *Daily update data at 9:30 AM*
(Price: 2026-06-04 | FS: 2026-03-31)

USD 34.69
-1.50 (-4.32%) Day Change
96.90
P/E
10.21
D/E
-52.1%
ROE
-3.6%
ROA
0.00%
Div Yield
-4.84
PEG
USD 34.69
Price
-1.50 (-4.32%)
Day Change
NEWS SCORE: 99

HROW Chất lượng tổng thể của cố phiếu Không tốt lắm ( Chất lượng = 54) và Thời điểm mua ...(Sign In to See)...

54

QUALITY

Signal
UNDERPERFORM
Signal Description
Company financial health is Not Good
Reason
Tỷ lệ P/E tương đối cao
Tỷ lệ ROE tương đối thấp
Tỷ lệ ROA tương đối thấp
Lịch sử ROE tương đối thấp
ROE đang giảm đáng kể
Biên lợi nhuận ròng tương đối thấp.
Lịch sử Biên lợi nhuận ròng tương đối thấp.

88 Sign in

TIMING

Signal
OUTPERFORM
Signal Descri...
Good
Reason
Lorem ipsum dolor sit amet
Sign in to see timing analysis
Unlock timing signals and detailed reasons
Sign in free

Chi tiết hơn, sẽ thấy rằng các yếu tố chất lượng Không tốt , Sức khỏe tài chính Không tốt , và khả năng kiếm lợi nhuận Khá , ...

Yếu tố Chất lượng 45%
X
X
X
X
  In Recommendations? Not in any sections
  Select Rate 0.00 From 30 days period
  Watch Rate 0.00 From 30 days period
  News Score 99
  Magic Formula Rank by ROA
N/A
  Magic Formula Rank by ROE
N/A
  Magic Formula Rank by ROIC
N/A
  Price 34.69
  PBV / Sector
43.20 / 2.65
  Earning Per Share -0.42
  PE / Sector
96.90 / 22.84
  PEG or PE/Growth / Sector
-4.84 / 0.11
  Average 1M Daily Value
34.36 M
GREAT
  Average 1W Daily Value
20.65 M
GREAT
Yếu tố Kỹ thuật 42%
  MACD
  MACD Signal
  MACD Divergence
  RSI
  Stochastic Oscillator K
  Stochastic Oscillator D
  ADX
  Avg 5 day Timing Score
Sức khỏe tài chính 41%
X
X
X
X
  DE / Sector
  DE Average / Sector
  DE Change Average (%) / Sector
  Current Ratio / Sector
  Current Ratio Average / Sector
  Current Ratio Change Average (%) / Sector
  Quick Ratio / Sector
  Quick Ratio Average / Sector
  Quick Ratio Change Average (%) / Sector
  FCF/Share / Sector
  FCF/Share Average / Sector
  FCF/Share Change Average (%) / Sector
Khả năng kiếm lợi nhuận 64%
X
X
X
X
X
X
X
  GPM (%) / Sector
  GPM Average (%) / Sector
  GPM Change Average (%) / Sector
  OPM (%) / Sector
  OPM Average (%) / Sector
  OPM Change Average (%) / Sector
  NPM (%) / Sector
-5.57 / 15.98
  NPM Average (%) / Sector
-10.17 / -16.38
  NPM Change Average (%) / Sector
20.31 / 113.39
GREAT
  Asset Turnover / Sector
  Asset Turnover Average / Sector
  Asset Turnover Change Average (%) / Sector
  ROA (%) / Sector
-3.57 / 8.16
  ROA Average (%) / Sector
-5.23 / 2.38
  ROA Change Average (%) / Sector
12.63 / 108.63
GOOD
  ROE (%) / Sector
-52.12 / -0.19
  ROE Average (%) / Sector
-34.82 / 7.40
  ROE Change Average (%) / Sector
77.37 / 371.95
GREAT
  ROIC (%) / Sector
  ROIC Average (%) / Sector
  ROIC Change Average (%) / Sector
Lợi tức cho nhà đầu tư 4%
X
  Dividend (%) / Sector
N/A / 0.54
  Dividend Average (%) / Sector
N/A / 3.09
  Dividend Change Average (%) / Sector
N/A / 15.45
Chi tiết đăng ký
X
  Analyze Date 2026-06-05 09:12:26
  Symbol HROW
  Name HARROW HEALTH INC
  Sector Healthcare >> Drug Manufacturers - Specialty & Generic
  Market NASDAQ
  Listed Shares 37.28 M
  Par Value N/A
  Calculated From Quarter
  Sign N/A
  Market Cap (M.USD) / Sector Average 1,224.86 / 9,638.91
Tin tức, Dự báo ước tính
  Estimation Consensus See at WSJ.com
  Full details See at WSJ.com
  Chart See in Chart feature
  News See at Yahoo Finance

Address: 1A Burton Hills Boulevard, Nashville, TN, United States, 37215

Phone: 615 733 4730

Website: https://www.harrow.com

Employees: 373

Sector: Healthcare >> Drug Manufacturers - Specialty & Generic

Description: Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.

ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic

HROW (ME)
Sector Peers
Bubble size = Market Cap

Click a bubble to view stock details  ·  Bubble size represents market capitalization share

News

Smart picks. Just WOW stocks/funds/ETFs. No noise like other tools.
HROW
HROW
USD 34.69 (-4.32%)
+ Watch + Port Chart